Grail declines comment on Hong Kong IPO plans

Grail Inc. (Menlo Park, Calif.) declined to comment to BioCentury on a media report that said the company plans to raise up to $500 million in an IPO in Hong Kong. The report, published by Bloomberg, cited unidentified sources.

Grail is developing blood-based tests for early cancer detection. Its ongoing observational Circulating Cell-Free Genome Atlas (CCGA) study aims to create a detailed atlas of cancer genetics, while its STRIVE study is designed to validate a breast cancer test and develop a pan-cancer test...